公开(公告)号：US20250064764A1

公开(公告)日：2025-02-27

申请号：US18827922

申请日：2024-09-09

Applicant: Hyloris Pharmaceuticals SA

Inventor： Thomas Jacobsen

IPC: A61K31/192 ,  A61J1/10 ,  A61J1/20 ,  A61K9/00 ,  A61K9/08 ,  A61K31/167 ,  A61K47/20 ,  A61K47/26 ,  A61M5/14 ,  A61M5/19

Abstract: An aqueous ibuprofen and paracetamol composition has a pH 6.3-7.3. The composition can be used as a medicament, especially for the treatment of pain and/or inflammation. The composition can be formulated for intravenous injection.

公开(公告)号：US20250064757A1

公开(公告)日：2025-02-27

申请号：US18629894

申请日：2024-04-08

Applicant: Duke University

Inventor： Kaitlyn ANDREANO ,  Ching-yi CHANG ,  Donald P. MCDONNELL ,  Stephanie L. GAILLARD

IPC: A61K31/138 ,  A61K9/00 ,  A61K9/70 ,  A61K31/00 ,  A61K31/192 ,  A61K31/40 ,  A61K45/06 ,  A61P5/00 ,  A61P35/00 ,  A61P35/04 ,  C12Q1/6827 ,  C12Q1/6886

Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.

公开(公告)号：US12226484B2

公开(公告)日：2025-02-18

申请号：US18487486

申请日：2023-10-16

Applicant: TRx Biosciences Limited

Inventor： John Brew ,  Daniel Gooding ,  Robin M. Bannister

IPC: A61K47/14 ,  A61K31/05 ,  A61K31/12 ,  A61K31/192 ,  A61K31/196 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/436 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/4453 ,  A61K31/496 ,  A61K31/502 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/58 ,  A61K31/7135 ,  A61K38/12 ,  A61K47/28

Abstract: The present specification discloses pharmaceutical composition disclosed herein comprises one or more therapeutic compounds, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C14-24 fatty acids, one or more free C14-24 fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more therapeutic compounds into the disclosed pharmaceutical compositions.

公开(公告)号：US20250049879A1

公开(公告)日：2025-02-13

申请号：US18716764

申请日：2022-12-07

Applicant: PM GROUP COMPANY LIMITED

Inventor： Prayudh MAHAGITSIRI ,  Chalermchai MAHAGITSIRI ,  Ausana MAHAGITSIRI ,  Thomas JAKSCHITZ ,  Gökhan SENLI ,  Günther BONN

IPC: A61K36/77 ,  A61K31/192 ,  A61K31/197 ,  A61K31/357 ,  A61K31/366 ,  A61K31/375 ,  A61K31/7024 ,  A61P31/14 ,  A61P31/16

Abstract: The present invention relates to a composition comprising or corresponding to an extract obtained from Dimocarpus longan for use in the treatment and/or prevention of a disease caused by an enveloped virus, in particular caused by coronaviruses such as SARS-CoV, MERS-CoV and SARS-CoV-2 or influenza viruses such as influenza A and influenza B and/or at least one symptom thereof.

公开(公告)号：US12220392B2

公开(公告)日：2025-02-11

申请号：US18405907

申请日：2024-01-05

Applicant: AFT Pharmaceuticals Limited

Inventor： Hartley C. Atkinson

IPC: A61K31/192 ,  A61K9/00 ,  A61K9/08 ,  A61K31/167 ,  A61K47/18 ,  A61P29/00

Abstract: An intravenous composition for providing relief for pain and/or inflammation, the composition having ibuprofen and paracetamol in combination for delivering to a human at each dose: a) approximately 125 mg to approximately 175 mg ibuprofen in combination with approximately 475 mg to approximately 525 mg paracetamol; or b) approximately 275 mg to approximately 325 mg ibuprofen in combination with approximately 975 mg to approximately 1,025 mg paracetamol.

公开(公告)号：US20250041375A1

公开(公告)日：2025-02-06

申请号：US18920079

申请日：2024-10-18

Applicant: POLY GAIN PTE LTD

Inventor： Shane Mitchell ,  Barry Kitchen ,  Gregor Macnab ,  Julian Neoh ,  Matthew Flavel

IPC: A61K36/899 ,  A23K10/33 ,  A23K20/111 ,  A23K20/121 ,  A23K50/20 ,  A23K50/40 ,  A23K50/75 ,  A23K50/80 ,  A61K9/00 ,  A61K31/11 ,  A61K31/192 ,  A61K31/225 ,  A61K31/353 ,  A61K31/7048 ,  A61P29/00 ,  A61P39/06

Abstract: The present disclosure relates to animal supplements and feeds comprising an extract derived from sugar cane, in particular, animal supplements and feeds comprising a polyphenolic extract derived from sugar cane. The disclosure also relates to animal supplements, animal feeds, methods and uses for improving or maintaining the health of animals to the benefit of improved food production and food quality.

公开(公告)号：US12201625B2

公开(公告)日：2025-01-21

申请号：US15748641

申请日：2016-07-28

Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Inventor： George Cotsarelis ,  Ying Zheng ,  Jen-Chih Hsieh ,  David Collins ,  Joan O'Brien

IPC: A61K31/473 ,  A61K9/00 ,  A61K31/192 ,  A61K31/404 ,  A61K31/437 ,  A61K31/47 ,  A61K31/506 ,  A61P17/14 ,  C12Q1/6883

Abstract: DP-2 antagonists reversed PGD2-mediated human hair growth inhibition in a dose-dependent manner in vitro by reducing PGD2-triggered apoptosis and maintaining proliferation of keratinocytes. Hair follicles from approximately half of the alopecia patients exhibited little susceptibility to PGD2's effect in vitro. SNPs in the human DP-2 gene were identified that are associated with hair growth inhibition by PGD2. These findings underscore the role of DP-2 in regulating hair growth and indicate that DP-2 can be an effective approach in preventing and/or treating androgenetic alopecia in patients sensitive to PGD2. Furthermore, the SNPs identified here can be used to identify patients who will benefit from treatment.

公开(公告)号：US20250017899A1

公开(公告)日：2025-01-16

申请号：US18431805

申请日：2024-02-02

Applicant: Research Cancer Institute of America

Inventor： Mohammed Amin Nezami

IPC: A61K31/385 ,  A61G10/02 ,  A61H33/14 ,  A61K31/19 ,  A61K31/192 ,  A61K31/22 ,  A61K31/352 ,  A61K31/353 ,  A61K33/00 ,  A61K38/00 ,  A61K38/08 ,  A61K45/06 ,  A61P35/00

Abstract: A method for treating cancer is described using combination therapies comprising the use of hyperbaric oxygen with histone deacetylase inhibitors, with and without glycolytic therapies. The patient is subjected to a hyperbaric environment of substantially pure oxygen. A predetermined dose of one or more HDACI substances is administered to the patient. In addition, glycolitic inhibitors may also be administered. Dosages, pressures, and durations are selected as described herein to have a therapeutic effect on the patient.

公开(公告)号：US20250012784A1

公开(公告)日：2025-01-09

申请号：US18707599

申请日：2022-11-11

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Ching-Chuan JIANG ,  Shang-Cheng HUNG ,  Chang-Hsun HSIEH ,  Pi-Hui LIANG ,  Ting-Jen CHENG ,  Hwai-I YANG

IPC: G01N33/53 ,  A61K31/135 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K31/405 ,  A61K31/485 ,  A61K31/5415 ,  A61K31/573 ,  A61K31/616 ,  A61K31/635

Abstract: Disclosed herein is a method for identifying and treating a subject having stages III or IV osteoarthritis (OA). The method includes steps of, determining the respective levels of chondroitin-4-sulfate (C4S) and chondroitin-6-sulfate (C6S) derived from a chondroitin sulfate (CS) chain of bikunin in a biological sample of the subject; calculating a risk score (RS) of the subject with the equation: R ⁢ S = 1 1 + e - f ⁡ ( x ) , in which f(x)=−9.3875+0.1356×(the age of the subject)+1.1493×(the level of C4S/the level of C6S) when the subject is a female, or f(x)=−10.3389+0.1356×(the age of the subject)+1.1493×(the level of C4S/the level of C6S) when the subject is a male; and treating the subject with an analgesic, a non-steroidal anti-inflammatory drug (NSAID), a corticosteroid or a combination thereof when the determined risk score is above 0.745.

公开(公告)号：US20250008984A1

公开(公告)日：2025-01-09

申请号：US18892950

申请日：2024-09-23

Applicant: Novus International, Inc.

Inventor： Bradley Van Lawrence ,  Robert Edward Buresh

IPC: A23K20/105 ,  A23K50/30 ,  A61K31/192 ,  A61P31/12

Abstract: Methods for reducing the risk of viral infection in animals due to consumption of viral contaminated feed. The methods comprise administering to an animal in need thereof an effective amount of a feed additive, wherein the feed additive comprises a mixture of organic acids. The methods can be used to reduce the risk of infection in animals whose feed may or may not be contaminated with certain viruses.